Eli Lilly announced that its experimental weight-loss pill, orforglipron, meets most of the criteria for the U.S. Food and ...

Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also recently announced a partnership with Walmart that will expand access to Zepbound ...

Eli Lilly's GLP-1 sales are rising at an unexpectedly strong pace, prompting its arch rival to make a surprising bid for an ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...

Eli Lilly's experimental weight-loss pill, orforglipron, has met key FDA criteria for an expedited review, boosting its ...

Eli Lilly and Company and Walmart Inc. today announced a collaboration to expand access to direct-to-consumer pricing for Zepbound (tirzepatide) single-dose vials available through LillyDirect.

The idea was beautifully simple. One pill taken daily to melt away those excess pounds. The new breed of GLP-1 oral ...

Eli Lilly & Co. has already produced billions of doses of its next-generation weight-loss pill, anticipating massive global ...